0001104659-21-134000.txt : 20211104 0001104659-21-134000.hdr.sgml : 20211104 20211104070025 ACCESSION NUMBER: 0001104659-21-134000 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20211104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 211377904 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm2131839d1_8k.htm FORM 8-K
0001761612 false 00-0000000 true 0001761612 2021-11-04 2021-11-04 0001761612 us-gaap:CommonStockMember 2021-11-04 2021-11-04 0001761612 bcyc:AmericanDepositarySharesMember 2021-11-04 2021-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

November 4, 2021

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

B900, Babraham Research Campus

Cambridge CB22 3AT

United Kingdom

 Not Applicable
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company    x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

Item 2.02. Results of Operations and Financial Condition

 

On November 4, 2021, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2021 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01Other Events

 

On November 4, 2021, the Company issued a press release announcing that the first patient has been dosed in its Phase I/II clinical trial of BT7480, a Bicycle® tumor-targeted immune cell agonist™, in patients with advanced solid tumors associated with Nectin-4 expression.

 

A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

 

Item 9.01Financial Statements and Exhibits

 

(d)       Exhibits

 

Exhibit No.   Description
99.1   Press Release issued November 4, 2021 regarding financial results and business highlights
     
99.2   Press Release issued November 4, 2021 regarding BT7480
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 4, 2021 Bicycle Therapeutics plc
   
   
  By: /s/ Lee Kalowski
   
  Name: Lee Kalowski
  Title: Chief Financial Officer

 

 

 EX-99.1 2 tm2131839d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

 

Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

 

-Announced interim BT5528 Phase I clinical trial results and preliminary results from ongoing BT8009 Phase I clinical trial

 

-First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression

 

-Cash was $259.5 million, which excludes $201.3 million in gross proceeds from Q4’21 public offering

 

-Genentech exercised an option in Q4’21 to initiate an additional program under the 2020 collaboration agreement

 

CAMBRIDGE, England, & BOSTON, November 4, 2021 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2021 and provided recent corporate updates.

 

“We recently provided a clinical update for our ongoing Phase 1 dose escalation trials in BT5528 and BT8009, the data from which support our conviction that the Bicycle platform offers a potentially differentiated approach to traditional targeted payload delivery,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “We were encouraged to see preliminary anti-tumor activity in both trials and across two tumor types, providing further insights as we continue to expand the application of our technology. We look forward to providing additional clinical data on BT5528 and BT8009 next year.”

 

“Beyond our Bicycle Toxin Conjugates (BTC), we are also making progress across our other programs, including BT7480, our novel, fully synthetic Bicycle tumor-targeted immune cell agonist (Bicycle TICA™), which recently entered the clinic, as well as in our partnership with Genentech, which is now being expanded to include a new program under the collaboration. In addition, we recently entered into a collaboration agreement with Ionis Pharmaceuticals to develop targeted oligonucleotide therapeutics, which we believe further demonstrates the potential of the platform outside of oncology. Our plans to advance our programs and platform in oncology and beyond are supported by a strong balance sheet that has been further enhanced by the recent proceeds from an upsized public equity offering completed in October.

 

Third Quarter 2021 and Recent Highlights

 

·Presented Interim BT5528 Phase I Clinical Trial Results at AACR-NCI-EORTC Conference. In October 2021, Bicycle presented interim Phase I results for BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful. A total of 24 patients were dosed both prior to, and after, the implementation of the EphA2 immunohistochemistry (IHC) assay, with a median of seven prior lines of therapy. Among these patients, preliminary anti-tumor activity, including three partial responses, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, was observed in seven EphA2 positive urothelial and ovarian cancer patients. Based on the totality of the findings, Bicycle expects the recommended Phase 2 dose to be in the range of 6.5mg/m2 to 8.5mg/m2 every other week, a dose that Bicycle believes is within the therapeutic range based on both preclinical studies and preliminary clinical anti-tumor activity. Bicycle plans to initiate expansion cohorts in urothelial and ovarian cancers, as well as a basket cohort that includes head and neck, non-small cell lung, gastroesophageal and triple negative breast cancers in 2022.

 

 

 

 

·Announced Preliminary Results from Ongoing BT8009 Phase I Clinical Trial. In October 2021, Bicycle announced preliminary Phase I results for BT8009, a Nectin-4 targeting BTC with a potentially differentiated profile as compared to an FDA approved, Nectin-4 targeting antibody-drug conjugate. As of September 30, a total of 11 response evaluable urothelial cancer patients had been dosed in monotherapy cohorts, including four patients in the 2.5mg/m2 dose cohort and seven in the 5.0mg/m2 dose cohort. Among the four patients dosed at 2.5mg/m2 weekly, three patients were observed to have at least stable disease, with a disease control rate of 75%, and one patient (25%) was observed to have a tumor reduction of 37%, meeting the criteria of a partial response under RECIST 1.1. Among the seven patients dosed at 5.0mg/m2, five were observed to have at least stable disease, with a disease control rate of 71%, and three patients (43%) were observed to have tumor reductions meeting the criteria of a partial response under RECIST 1.1. The magnitude of tumor reductions ranged from 44% to 89%. In both cohorts, BT8009 has been tolerated, with no dose limiting toxicities observed to-date. Dose escalation remains ongoing, and patients are currently being enrolled in 7.5mg/m2 weekly and every other week cohorts. A total of 14 clinical sites are active globally, including nine outside of the United States, and Bicycle expects to have up to 21 sites active this year.

 

  · Announced First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression. This is the Company’s fourth product candidate to enter the clinic in as many years and is its first immuno-oncology asset to enter a clinical trial.

 

  · Raised Gross Proceeds of $201.3 Million in Public Offering. In October 2021, Bicycle Therapeutics announced the closing of an upsized underwritten public offering which yielded gross proceeds of approximately $201.3 million. All of the ADSs in the offering were offered by Bicycle Therapeutics.

 

·Genentech, a Member of the Roche Group, Has Exercised an Option to Initiate an Additional Program. Genentech has expanded the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. Bicycle and Genentech are collaborating on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets. Pursuant to the terms of the February 2020 agreement, Genentech has exercised an option to include a new program under the agreement, triggering a $10 million payment to Bicycle. None of the compounds in Bicycle’s wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration.

 

  · Bicycle Provides Update on BT1718, a First-Generation BTC Targeting Membrane Type 1-Matrix Metalloprotease (MT1-MMP), which is Currently Being Investigated in an Ongoing Phase IIa Portion of a Phase I/IIa Clinical Trial Sponsored and Funded by the Cancer Research UK Centre for Drug Development (CRUK). Although there has been an acceleration in the second half of the year, enrollment in the Phase IIa trial has been slower than expected and remains below projections. Currently, five of the six planned clinical trial sites in the UK are open for enrollment, and CRUK may open up to two additional sites.

 

 

 

 

·Announced Publication of Preclinical Data from BT7480 in the Journal for ImmunoTherapy of Cancer. The article, titled “BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism,” outlines BT7480’s potential to elicit rapid reprogramming of the tumor immune microenvironment, which was observed to lead to complete regressions and anti-tumor immunity with only intermittent drug exposure in syngeneic mouse tumor models.

 

  · Entered into an Exclusive License and Collaboration Agreement with Ionis Pharmaceuticals to Develop Targeted Oligonucleotide Therapeutics. In July 2021, Ionis exercised its option under the terms of a December 2020 evaluation and option agreement and entered into an exclusive worldwide license and collaboration agreement for tissue-targeted delivery of oligonucleotide therapeutics using Bicycles with high affinity to the transferrin receptor (TfR1). Bicycle received $45 million upfront, which included a license fee, an option fee and an $11 million equity investment. Bicycle is also eligible to receive development, regulatory and commercial milestone payments and royalties for programs developed under the collaboration.

 

Financial Results

 

·Cash was $259.5 million as of September 30, 2021, compared to $136.0 million as of December 31, 2020. The increase in cash is primarily due to financing activities, including net proceeds of $102.6 million from Bicycle’s at-the-market (ATM) offering program and net proceeds of $15.0 million from Bicycle’s debt facility with Hercules Capital, as well as the $45.0 million received from Ionis under the 2021 collaboration agreement, offset by cash used for operating activities. Cash of $259.5 million at September 30, 2021 excludes the net proceeds from the public offering received in October 2021.

 

·Research and development expenses were $10.5 million for the three months ended September 30, 2021, compared to $7.4 million for the three months ended September 30, 2020. The increase in expense of $3.1 million for the three months ended September 30, 2021 as compared to the same period in the prior year was primarily due to direct program spend for BT8009 and other discovery and platform related expenses, as well as increased personnel related expenses, including $0.6 million of incremental non-cash share-based compensation expense.

 

·General and administrative expenses were $8.1 million for the three months ended September 30, 2021, compared to $7.2 million for the three months ended September 30, 2020. The increase of $0.9 million for the three months ended September 30, 2021 as compared to the same period in the prior year was primarily due to increased costs to support operations as a public company and increased personnel-related costs, including $0.6 million of incremental non-cash share-based compensation expense.

 

·Net loss was $14.7 million, or $(0.59) basic and diluted net loss per share, for the three months ended September 30, 2021, compared to net loss of $10.1 million, or $(0.52) basic and diluted net loss per share for three months ended September 30, 2020.

 

 

 

 

About Bicycle Therapeutics

 

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

 

Forward Looking Statements

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s anticipated advancement of its product candidates, including BT5528, BT8009 and BT7480; the advancement of Bicycle’s product candidate pipeline; the anticipated design of, initiation of, enrollment in and progression of Bicycle’s and its collaboration partners’ clinical trials; the availability and timing of data from clinical trials; the therapeutic potential of Bicycle’s product candidates; the development and potential commercialization of potential product candidates using Bicycle’s technology and under its license and collaboration agreements with Ionis and Genentech; the potential for Bicycle to receive milestone payments and royalties under its license and collaboration agreement with Ionis; potential site expansions in CRUK’s ongoing clinical trial of BT1718; the therapeutic potential for Bicycles in multiple applications; the potential of Bicycle’s platform to develop potential precision medicines; and Bicycle’s ability to achieve planned milestones. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle’s and its collaboration partners’ abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Bicycle’s product candidates by Bicycle or its collaboration partners; the risk that Bicycle may not realize the intended benefits of its technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; risks related to Bicycle’s ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market products; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2021, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

 

 

 

Bicycle Therapeutics plc

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
Collaboration revenues  $4,333   $3,842   $7,926   $6,542 
Operating expenses:                    
Research and development   10,513    7,363    31,924    23,091 
General and administrative   8,114    7,154    23,596    18,351 
Total operating expenses   18,627    14,517    55,520    41,442 
Loss from operations   (14,294)   (10,675)   (47,594)   (34,900)
Other income (expense):                    
Interest income   24    72    61    655 
Interest expense   (823)   —    (2,164)   — 
Total other income (expense), net   (799)   72    (2,103)   655 
Net loss before income tax provision   (15,093)   (10,603)   (49,697)   (34,245)
Benefit from income taxes   (415)   (465)   (915)   (668)
Net loss  $(14,678)  $(10,138)  $(48,782)  $(33,577)
Net loss per share, basic and diluted  $(0.59)  $(0.52)  $(2.06)  $(1.81)
Weighted average ordinary shares outstanding, basic and diluted   25,039,990    19,426,833    23,719,124    18,504,013 

 

 

 

 

Balance Sheets Data

(In thousands)

(Unaudited)

 

             
    September 30,    December 31,
    2021   2020
Cash   $  259,524   $  135,990
Working capital      242,695      132,594
Total assets      281,333      161,152
Total shareholders' equity      170,823      95,460

 

 

 

 

Investors:

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com
617-203-8300

 

Media:

Consilium Strategic Communications

Sukaina Virji or Mary-Jane Elliott

bicycle@consilium-comms.com

 

 

 

 EX-99.2 3 tm2131839d1_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

 

 

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression

 

-      BT7480 is the Company’s Fourth Product Candidate to Enter the Clinic in the Past Four Years

 

-      This is Bicycle’s First Immuno-oncology Asset to Enter the Clinic

 

CAMBRIDGE, England, & BOSTON, November 4, 2021 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT7480, a novel, fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) targeting Nectin-4 and agonizing CD137. Preclinical studies have demonstrated that BT7480 activates CD137 only in the presence of Nectin-4 expressing tumor cells. The Phase I/II trial of BT7480 will be conducted in patients with advanced solid tumors associated with Nectin-4 expression.

 

“BT7480 is our first Bicycle TICA to enter the clinic and is one of a new class of tumor-targeting agents,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “Overexpression of Nectin-4, a well-validated tumor antigen, has been observed in several common tumor types and is associated with poor disease prognosis. Activation of CD137, a co-stimulatory receptor expressed on multiple components of the immune system, can drive anti-tumor immunity, but activation outside of the tumor may give rise to toxicity. Preclinical studies have shown encouraging results, and we look forward to studying the safety and efficacy of this unique asset as we begin the dose escalation portion of the trial.”

 

The Phase I/II multi-center, open-label trial will evaluate BT7480 administered once weekly. Enrollment is ongoing in the Phase I dose escalation of BT7480 given as a monotherapy, and the Company plans to evaluate BT7480 dosed in combination with nivolumab in future Phase I dose escalation cohorts. The Phase I portion of the trial is primarily designed to assess the safety and tolerability of BT7480, and to determine a recommended Phase II dose (RP2D). Following selection of an RP2D, Bicycle expects to initiate a Phase II dose expansion portion with the primary objective of evaluating the clinical activity of BT7480 as monotherapy and in combination with nivolumab in patients with Nectin-4-positive tumors.

 

About Bicycle Therapeutics

 

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

 

 

Forward Looking Statements

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical development of BT7480 or any of Bicycle’s other product candidates or programs; the expected design of Bicycle’s clinical trial of BT7480; the anticipated progression of clinical trials; the safety, tolerability or efficacy of BT7480; and the potential benefits of BT7480 or any of Bicycle’s other product candidates. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials and clinical development of Bicycle’s product candidates; availability and timing of results from clinical trials; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; expectations for regulatory approvals to conduct trials or to market product; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2021, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

Investors:

 

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com

617-203-8300

 

Media:

 

Consilium Strategic Communications

Sukaina Virji or Mary-Jane Elliott

bicycle@consilium-comms.com

 

 

 EX-101.SCH 4 bcyc-20211104.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 bcyc-20211104_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 bcyc-20211104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 7 bcyc-20211104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 tm2131839d1_ex99-2img001.jpg GRAPHIC begin 644 tm2131839d1_ex99-2img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !Y 1@# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBODG]N MGQ7XG\"?L4_ME>-?!>MWOAGQCX,_9;_:!\7^$O$>GW8T^^\/>*/#_P (_&.K M>'=6TK44*&RU#2M7TZSU>.:3<8)'64EE&VOYMO\ @VV_:U_:<_:.^.'[2^B_ M'KX^?%/XR:'X8^&'@S5?#NG_ !(\8ZUXDMM!U"_\67"7.HV@U!38OJ%^A4R3 M6>(<#_1F$(0 _K_ **9&28T)WY**3Y@429*C.\)A ^?O! %#9V\8I] !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?P M@^-/^"@G[:UC_P %P;;X#VO[2WQ63X-M_P %)/!GPOF^'$?B98?!Y^'6H_'G M0O#-]X9?1RI,MA;>&KB:P$9!!AA3<&Q0!_=]13(L^7'E0IV)E57:JG:,J%R= MH'0+DX QDXI] !1110 4444 %%%% 'QG_P %$_\ E'Y^W9_V9W^T[_ZI3QG7 M\I7_ :E_P#)P/[5W_9&/!O_ *G5U7]6O_!1/_E'Y^W9_P!F=_M._P#JE/&= M?P__ /!"S]N?X$_L$^(?VMOBK\$KOQO>7LH-^IU[4=/N_%ND0ZBTDI:%KWQG\ESO$M_.5:=P#_1; MHK_.VT77O^"ZW_!)&*'QKXETGX\>'/A%X;O; :QHGC"\T;]H+X$-:2R0B2U\ M0CP[XM\7Z+X&CU)8D73M9TS5O#.J11&%VU#P[(O_ CT/]7W_!+3_@K;\)_^ M"CWA2]T(VMK\-/VB_!FBR:SXZ^%4VH7-WI]SHMI+!I6H?$+P'?WX@N_$?@E= M9UC3M.O;>_>*\T._DBMKW=>KOD /V+HIJ#"(/FX51\Y#/P /G8$AF_O$$@G) M!/6OX[/^#B#]L#]J;]G?]L+]GOPE\"_V@OBG\(_"NN_!.R\2^(M"\%^+-3T# MP_J&H?\ "SO%.G3:UJ]A /*NG>VTO1]*D9/OI)GD-R ?V*U0F9%X*E]TC8 S M@/N/7MZ\539%E6+SG,56>EHT*$>:K7E)I1 MIPDV]+/U/Q?\0?!G@+3YM6\:>*='\-V*^9Y4NJ745L\[AR&AM;.X(N;UQ_"+ M-7+#:4 CVFOEK5?V[O@-I$S1V=[XBU\%V!N=-\/S+;-R?WD4FIZA:(8GQNC( M15V,I"C@5\5>"_@?\:OVO_$K_$SX@ZS%H_AG5-UM%KLUJ9$2SMG"_#D\ MQ ,: P2ZD[ W(0L6D+%1]G^&OV!_@9I=ND6JQ^(O%$_E(K27^K#3T$@0!FB@ MT>'2+BWC+ E;>2[N9(E(C>XE=3(W\FX?Q,^D]XL5)9YX2\!<%<%\#NO*GDV> M^+*K_P!O9Q@'?V6;Y3A<([+ XJRK8=S2O3J0O4J-<4)N4<5I.,80TI0YCIO!_P"VS\"O M%MS%IK>)+OPU=W,IBMY/%>E26-C/*S86$:O9?:=)@,9)7_2KI">[9P3]4Z?< M0W=G:ZE:3:?-97L$-W:WUHT=S;7=K*1)89H\1NC*R':>? M@KX@_P#!/?P#JNGSO\/-8U7PKJZ*6AMKZ[FU_0I'Q(5@FCU6Z?6;)"?+B-Q9 MZ[.( 7D2PEVI ?GSX5^&/VOOV?/&)\-:5X)U7Q;X5:^*WNAV%Q;W?@76+5YM MDVJZ-K[16T6B:DBI]H,VNVMK>:T=LM[#%\?/#SB#+\O\9/#2IQ1 MPKBJT,+5XZ\-,/5Q]#*:]?E2Q6:9/&7M,5EUG"G#E4:F&K\^(7.XN)Q8_P / M_"SBC*L9G/AWQG2R?- MUS_$#_P6"_:#_P""C_\ P3O_ &][GQ3X7_:4^/:? #X@^([?X[?!7PSJ?CK6 M-3\ ZM9:+K'AK5OB5\)[O3+YGTX>'O#'BG48/#5A\-[=O*N? NIZ"J*J>)PH M_KS!SHU*<*U*=:JL536,P]6O-UJWU3$*E5A3G4=.'L>6=56P=VZ-G=.49./X M0X5*?V9_P!H?P#^ MU5\"/AG\??AC?6]_X-^)7AO3M8MH#/'<3:-J]\UV"'5%\AW].X M/;@>O/UZ]ZS-:U;3-!TO5->U:YALM*T+3[_4M8U"X)$=AI=C9R:A?7+D9;RX M;>+S' !(120#M /\'M[_ ,%"_P!MK_@H7_P5EM?AU^RS^T!\:/"GP \;?'C0 M?"GASPM\,_'FJZ%X5@_9\\&:EH^D^-?B"UA;[0T^J^#M%\0_$_5M:B)ETE_$ MYT%';45\'$M4U4DHWBJMI.ES?S*+T*D^L(II=VW9(_O279SC. M,]@!V'^?_KUEEDMQ^/'Q0_: M8\6WOPV^#%G?3^#%NY5>'176VG\5:>US(EOJ_B#4W_X\/#=S;B*]TS:-TD#Q M%L[5 _%O%_QFX:\)LG=;'X+-,]XNS.I'+>%^$^'H<_$7$V9M1J_4#G55%5 M:+E*+J8F4^:*IQ:7*DYS@K7KIINB6$T3(R/%>ZD/)9661F(+5Y?8_\%$/@I(RP7?A[XAZ? M!)@_:9-%\/7$,.X8V$Z5XEO%<*" 'A>1#C,;NN&/(_"?]@3PK:6%M?\ Q5U' M5-=UJ0>;<:%I&KK#H=JC#>+.:]CA75KJ]A!,,]];W,0GFC,R K)\OM=S^Q%^ MS?>6LD2^"KVSEN,F.[B\:>,6OH%;)!C&L:_JL*,H(^0VD2@J (8P/+'XKA\; M],WB3#X?B##X/PD\.\OS*E]:I<#<81J8O-52J^_AH9O6P\IPI9K4J>SABH,_@%K?B/6KO3;J&6'08+A+;Q=I^)!MDTC7AY;7MN@*_;K*2.(7" M;]H!RB_;O[-?BGXSZOX7;2?C+X2NM'UG1_)AM_$7VK3&/B6V10L9O-,4FXLK MR% INIY0//ERY:)O,\S[_P *O%+Q(QW$U3P_\9O#S$\+\8T\-*IA>)4?J/CS&&3@C M^F!@_@/;VK_./\;C;_P<062^G_!5SX=#\OVF?"(K_1P3;A&W!OW:MN5MX8%0 M00^!NSV; R#G'2O\Y#QOS_P<061]?^"KGPZ_]:9\(U_2,*D:G.HJRI5)4?65 M-).WWV^[S/R>?)SQM\?LHI_X5+1_-W/]'E>@^@_E2TB]!]!_*O@K]N;_ (* M?L\_L!_#:X\?_&WQ*;;6];_M:T^&'PVT.W&I^//BAXET6.WFDTWP=H4S16KP M17NMZ39>(?$5U>6'A[15U2%M7US3-1>*R:A'WM17^?+\0O\ @I#_ ,%B/^"J M7C#Q3X:_93T3XN^ _AOIC+#'X)_9D_M[3(?"VF7[O_9\?Q,^--MJ'A?6-2U# M5-/,<>LSS^--,T2\NC=7222$L0#_1+/B;8_';3OA39ZE8V.H:!\;8[SXY_ Y[;S(DT_1O^$NTO4?&> M@^"9;_55N(=&N? ^M^ ]4@A-N==76W5_,_J__P"";/\ P5]_9^_X*$Z)8^'( MK^V^$?[1MNCW7B+X&ZYJT=S*]0 /V&HID0 BC R0(T +-(S$!1]YI296/JTA,A/+G=FB@#X MV_X*)_\ */S]NS_LSO\ :=_]4IXSK_,U_8N_9<\8_MG_ +3'PG_9M\%2FSU' MXA^(8H]=UXQ+/'X1\#Z=<#6?&WBF:W8JMW>Z)X3T+5=3TJW+*->;3X_ Q8#6 M2:_TT_\ @H+IU[JO["7[:^E:=&DFHZK^R/\ M'Z9IB,.9+[4?@YXUME4$GAE M4(1TWBZK^VO\ &WQ!=V=M+K/AC]F77AHL!*AK<:_\0O 6 MFWK_Z]Z%( M(!!# @$,,$,",@@CC!ZC''I2T 8>OZ#H_B;1M5\.>(-,L]9T'7=/O]*U?1M1 M@6ZL-4T[48FAOK2[A=65XIHI)(W1@1M<[<'#+_ K_P %$/V>_$7_ 1._P"" ME?P@_:8_9M4Z3\(_&7B34OB5\-M"3?;Z/HECIE[%9?&?X!W9 1K;PM-H'BPK M:E"3:>#?&&CW"R,W@[>?] :OY0O^#K/2K&3]G[]E/7BL"ZKI?QK\7Z59EAR= M*UCP5;ZEJ9Z_>_M30]%)QV()Y)H _J-^'GCGP]\3_ '@;XE>$;MK_P *?$/P M?X9\<^&+YEV->^'O%NBV6OZ+=LF3L:YTW4+:8KD[2^,G%?Q'?\'0Q'_#;_[, MX';]GJQ!^I^*_P 0&/ZG_)K^EC_@C1KFL>(_^"7G[&FH:L5%[9?"FZ\/VA'W M5L?"OBOQ%X-\,G_=.AZ19@>QK^:;_@Z$=7_;?_9H*@#'[/=DAQW9/BO\0%8_ M4D"QZP_I]6DZ_P#Y1YC6C4]G47+_ !I1G&A_U\Y';\#^ MX*YGCMH9IG&V) DN?7:\DTQ/L54''U'>OPWT:TOOVN/VJ;ZYN)IG\+RZI=ZI M(;8A8K?P-X7U&:STVUMB1_K=0"V]OK Y;7Y .,&OVZ\1:1/J^A:OI=K=?89 M;^PNK&WO%@^TFU>[CDC>X\GA7V;PX5F"Y0$L,D5\X_L_?LM^$O@3<:EJEGK> MJ>(O$FM:4=(O]6OU$4?D&X^V2Q0VT6Z.!#.I,:*["- $R3@U_+'C9X8<1>*_ M%/A/D5%4H>&F18W$\2\72O%.KBUH5'R*RYI5'YGZMX:<993 MP)P_QMF;GPPVUEI5A#IUE:VZ[(+>UM(1!;V\"@ "&&)4CC& B@8%; ML8Q'&#U"*/R4"JD. D9R,+NZY.<<]L]?D\,DK)82C&&'HJ.WNV@K*RZ=-#\DYIS]I5J_[QB*L\3BVY.3>*JMRJ.4G M=RDVVW)MMN[;;;;=48*[NF#D\Y[_ /UZDIA((;..">V,M:D:;BY M5(IJ";W^9!)CIY>?SS]#GTZ]J_&3_@NK^QW)^U MS^P=\0KKPSHTE]\5/V>([GXW_#DP ?VC?Q>%M,$WCCPQIA,F?M/B+P8=6;10 MJ9/B_P /Z"?NAB/U.\5?$[X>^%]"+=@LRRW&8G$8?!YM#'8C#TXSQ&%C*,GA8RJ.$9R2BF MN::=-7;O;38WJ4<13ITYU5:G4O[*ZDKV2NUS;I+2Z5D]&[Z'\:O_ :]_MA0 MZ9K/Q@_8?\5:DAL->BNOC'\'$O"JQ'7-(LK:Q^*'AI28W+"YT ^%M99^%+#1[7Q[\(]5O PDUV^M? M$DQ*O+Q_HC?"[XE^#?C/\,O 'Q=\#ZDVK^!_B7X+T'QYX:U6XB\BXG\-^*M( MM+ZQGE!>,:3?06-Q$VM6! >PO#^Q_#XAPQ+>-4*D M!2H^$_\ @V$_9!_X1WX?_%;]M?QEI9CU+XD2W'PE^%,NIVN)4\">$K]M4^(/ MBBUD>-D>W\3^,GTOP5&Z2QR)'\+=6C;Y+K#?D3_P5Q^.'B[_ (*1?\%39?@Y M\)'F\4:1X/\ &V@?LN_!_3;>V74=#U+5;?7WT;QEXNOK>-F1M*U3Q[>^)8H] M<1F2Z\'^&=(NE)#@U_>_^S]\#?!W[-7P/^%7P$\$I*/"WPG\!:)X+L=0G(^V M:HVCZ?;C5?$6L2ECNU3Q%J0N=8U63_'B'7_LX!EETRR+0Z/;D@G'_$^(N\ C']CD-DL*]Z_8 M\^#UM\,?A-I%])?&^GZ?KVN73E5N8QJ%O#>:-I,_P#$6TS3+FWM"!@> M9&V02RXD^*_[*O@WXS?$K3?&WC+6]3>RTSPYIN@P^'--D:PM76RO=9EN)+C5 M(QYET9;C5"K69 $?D[71@ZFOK:U2.."".-3'$L,2Q1$;3%$J*$CVDG:44!2, MG&,=J_FGA+PKX@K^/_B3XN\;QI3P%*.1Y/X9J$X_N,CP^"C6KUYQ5^64Z]6K M%IVESRE=)NQ^N9[QKDT?"'@_PXX8E5C7J+$YOX@3Y7"%;/Z\JE.G0C)M2J4Z M6']E)I)1]I&*;GRI@% 9$'2).Q&,CG [= 2 M>>HSS^O7J.GH*F0@HA'0JI&>N" 1G\*_I>+=Y<^E2(Q%:3C0A&+DU.R>B2E)MW22C%MO0 MZ=BFS<%W^V>F/R/(_P XS7^<9XVQ_P 1#]C@8'_#UOX=8'H/^&F?"/'X=*_T M-/ 'Q#\)_$?1CK_@W5H=9T=KR\T^WOX Y@FN=/GDM[M8IWXG031L%F3_>L^KUU6V^GW%5<-B,'7GA<;A98;&4U^^C*+C+=+DDG:2E%N+<6M+H_P!' M)]L>]LHI9!)+++]Q(HP.O(&%&3RP ^9B:_S\?^"I'C3QY_P5+_X+$Z;^S#\, M+I/[#\">-K/]F+P%=1*V[2%\+:I/J7QF\?ZDH,A:VTWQ3:^.)79>9/"_@;2W M"@OMK_0,D\M3AR%#O VX_P#/=I88[=0.^7B4$=R!G -?Y67[(7A?]MGX^?M* M>)/%7[%T?CBX_:&?1O&?Q-O]9^&GB?3/#?C'1-"\0>(]/\*>(?$.EZMKNL>& M;:VMDU3QGINC:I&EW-''%KDQ\QXT+UZ,-WZ?J2?Z9'[+G[,GPE_9 ^"G@KX# M_!7P]::%X.\'Z+!&^VV$&K^*/$*06T.M^,?$=R GVKQ#XCOXGU36KIU5I]0N MII%"H%0?2 Z#/H/?]>]?P+K\"/\ @YO*@G6_VP4) )6']I/P7+"I(R5BE3XF M2))$#Q'(DDBN@#*[@ABO_"A_^#F[_H.?MC?^)'^#?_GDT35K.][@?W8^-?"? MAGQ_X=UWP9XT\/:;XG\)^)=+U'0?$7AS6[2+4=(UW2K^-4N=(O=.E6_P Y3_@I!^S)XM_X)%?\%$M(U_\ 9]UJ_P##7ABROM#^ M/W[-GB:8OJ$O$*L6;4M#T'Q%HFK^$CH+,7U[PC!I5[+ME\5R M*OUU_P *'_X.;O\ H.?MC?\ B1_@W_YY-?/7QO\ ^";O_!=O]I&Y\-3_ !Z^ M%/QS^,6H^$+/5;/PS>^/_BI\._&$WAU-:NSK%PEM=:U\2?(M5FGTG1%*1@QP MY51A0*@#^^W]FKXX^'/VF?V?_@]\>O#, M]"^,'P[\,^.HM*>=;JYTF37-'M M#KGAN[G54\ZZ\.:K)/I-[.H GGL7VK@AB5\??\$?O@S\6/V=O^"='[/7P>^. MOAJ_\ _$SP$GQ53Q-X9UC5+#6]2T+3]3^-WQ#\1>&[8WVE7=]I46GR^$;S35 MACTZZGL(H/*2QN9XHEFE* /T'^(/@_2OB%X%\<> ?$ 9]"\:^&?$GA#5D4JQ MET;Q3HEYH&I^&YM9$=U>"5&5F!!.K7^=O_P3_P#^"TO[5/\ P33>Z_9N^-'PYU+XE_"G MP=K<^AW'PH\6G@KQ;X?U+0 MIUA_LWPYK7AZU9)(_P"C+1O^#EO_ ()MW_AZTU?4)_CWH>IW%L9YO"M[\*#) MKEO-'$)7MR=&\2ZWH,4\\Q>+%]XAMCNY=XVW,0#^A3A,=;DP^@WOBN]M956?PO,JU?V\?\ @Y<^('Q9\-:[\-?V)/A_ MKWP1TK6K9K2Z^,OCJ_T"3XM75CJ$G]GSR>!O!UA>76A?#R:%&_LBZ\;ZIXE\ M8ZG;S,=,T?2/!=S':^)9_H3_ (-^?^"6OQ.\,>/=7_;T_:A\#ZCHNKOIA3]G MSPUXZLM5?Q;<:YXB1KOQ#\9M1T;6HH=6T"TNO"\UO:^$;?6(X-4\4:SXG\9> M*]5M=*U,^&->U4 _I\_9+^!$'[,O[,7P%_9Z34;/59_A!\+O!7@O4=;L;>2S MLM=U[0=,LO\ A*=;LK.;]]9V>L^(%U#4;>UF)EMHKI()"7C8G^/3_@Z)R?VW MOV8RPPW_ SKIN0.0#_PM;X@9&>^#7]S<6?*CW-N;RTW-N#[CM&6WA(P^3SN M$:!LY"*#M'\,O_!T5_R>_P#LR?\ 9NVG?^K6^(% ']SM9KX<3(&7(D2,DD$UI5X]\5?$GBSPAX-USQ#X)\+1^+_ !'8O/)9Z!MBL6\N MA/$8V%##4Y5INA@<.GCL=-J$DJ& C/$::# M+' ].!GVS;A"1P1HJ*0D:+A 0HVJJX5200O'RJ1D#KZU^:GP;_;PTO4+^YT# MXT6=OX3U3^T+B&PUS3[:[&BP%)S'#IFL::CS:OIEU9J&BO;VZC.D22HS13I" M 3^@OA;Q5X=\6V,>I>&=Q7F?B-\7? ?PKL)-1\9> M(M(TM(XF\FSENHUU2[=F\=7TDHVRPZ;I M'G:?H&F,.<26L9T*)^H!@3%@8'E1X'H-HP/PZ5\Q?LV_ JP^!?@ M%-(>2TO_ !AKS+?^*]6M79H;K5 A>+3[61PLDEEI4+?9K>1UC::&-68;G^7Z M=A(,,1#!P8XR'!R&!4$,#W#=0?0T?1O\-\X\.N":D^*:?/QMQECJ_&'&6)YU M)4<[S2?M)959=<%AZM-^U^U?ZGJLH@SH\8>,,GXNXII1X6H+!\'\.9=0XW_ ,:OA;XOO?AK^S5;Q7XM]>T[ M1?CIH?B/7-*\4NX8;;+X;>+O#?Q4\2?VM(DD>EW%YX0\+MM;Q!%G^Z#6-(L= M;L+_ $?4K.VU'3=8MYM,U.UO:=<>>MW;.%C.#%'-*MNO!SGYU(\U/\LW M]N#]CS7_ -FC]O+XL?LA?#ZSF\5ZA8?$ZRT7X0Z%8R_;M3UC1?B/%X6UGX0^ M&)X<#;JSZ)XP\/:1XD4@8O+FX! QBOZ&/R@_&%!_N$3;L7:-J[5VKM*87 P-A"E<# VD KTP,8KY$_8@_9>\-?L9?LI_!7 M]G+P\MO(/AKX*L8O$>JVZ^7%XC\WUXHVJ%SG SZX&,T +6>KEI)059%61^6V,K8) P P!'/4GG!Z5H5^ M7W[17[3/[07P<^))LY/"7A[3/ IU2X;1+T6TNH_\)CI:WDJK&^K,470]62U5 M))H-K)',S %T :OS;Q/\3>&_"K(J'$?%%'-UEM3%2PDLPRO)LRS>EE3E2A.> M+S*67PFL!A'":IPQ&+2H5*T71B_:1:?U_!?!.<<>YO\ V%D53*HX]T)8BG2S M/-897+$>S;M2P*FG]&]= M9EAO/#'BK4=/LM02Z11YPTYBX?4[5)-R0WBKBY55G ?%>YW?C+PAI6G1ZCJ M7B;P[86"PI(;J^UC3K&V*,@<.LTLB*4((*[OF((R,GCU,@XSX3XLR+#9WD&? MY;Q%D^(P=/'RQV%S' 8F-.E6:Y99O@Z%L3@J-&SES8R-.*K0E12E4BVO&S?A MS/\ )79IP]FN!S/"UY82=3%Y;5P^&JNG)KDPN,4*D<8XR]YJG4G&,91J M7Y9*_:+)$P>15)VKC.,9[8 ]U(QSV^E?D?\ M^_%G3]8N]-^"V@.)[[3]2MO M$FMK;@&8:S>1ZS9Z+8DC)\P(9'V-]S4IM"(&'(KUSX_?ML>&/"NCZCHWPJU: MT\5^+;E9+6WU;3HVU7P[HWF,J3W%S-!-Y&K21XD%LEOOCA8H7/E!UD\9_9$_ M9TUKQUXDC^.'Q,6673/MEUJNAVVLM]JUGQ1J][,;S_A)=7D(9)+&66;[=I ) MYCEC<@<"OY,\%7)Q15XHK8>GXFSI*<:JE*FDUS3E&-*,74_0/]G;X=S?##X.^"_". MHN5U*UMKB_U1&'_'M?\ B"ZEU.\L@03Q:S74EL.@RF0?3^ 7Q@%'_!PSI@7[ MH_X*K_#8+_NC]I?PAC]*_P!&^/:H'.XNI#\ ?,$Y./7&?;)K_.2\:;?^(AS3 M]OW?^'K/PXVYZ[?^&F/"&,_A7]D<*9)0X9X:R'AK RG++>'A1P>*O&_O5,-!*2O;FE)K1H_G[-LTQF=YQF^8S7VL?B MZU2I+31)>PE"UNBC=WN?Z.03:S2@IDL6,C'Y8X@ENLZDG@$F#KT!&3T-?Y_7 M[.7BA/\ @C+_ ,%MO&/A3XOYTSX3ZUX@\2_#S4_$D4C6FGV'P>^,^K:/X@^' M7C%2%9]7T#PY-:>$-7\9JJE]%U2P\5X!:(5_H'KT'T'\J_F;_P"#A'_@E]\2 MOVNO#'A#]IKX Z-<>,/BW\&_#EWX7\6> -'M);GQ5XU^%-OJLWBR&?PE96J2 M3^(_$W@35+CQ)J=OX(A#7WCG2O$5QIOAN%O&^F:#IOBOZ X#^ERSEBFL[6:" M19H9;:"6&5+C[6DL4D2/'(EUEOM*NA#+<;F\X$29.[-6:_@,_P""9G_!P#\2 M?V.?"6@_ +]J3PAXF^,'P<\&Z:GA[P=K'AZ?2E^*WPKT_3)/[-MO"]OI&NMH MGA_Q!X0\-V\4>E6.F:OXV\&V>AZ;8P6/AWQ+?V=K9Z0W]&&E?\'#G_!*NY\- MW.MWWQV\5Z+JBQ&:+P;J'P9^+L_B"X8J'%I9W&F^%M8\(3."QC68>)K:QDV% MHI1"T3, ?N'7XZ58Z;+\2/%_PUM[ M'7]*^&?B/4I[:[L?".H:;)J.EWOB/4;'0;F#Q;XTTCPTVOZUH6@7T$']A:]> MQR>'+3\@?VZO^#F]O%'A_P 0_#?]AOX;ZUX4&LZ?>:+=_'/XN0Z18:YID=X9 MH;FY\#_#G3FUBQTV;4U99M/\0>/?%-K?8:.?3_ %Y,4OHOFG_@B[_P $B?B= M^UC\5M%_;,_:Q\.^(H/@;I'B1?'&@V7C2%K7Q1^TO\0I;HZU!XCN;:::2XN/^%D:FZZ)Y]Q:P^+;_P *@']W?A+Q/H_C;PKX9\9^'IKF MXT#Q=X?T;Q/H<][IVI:/>3Z/K^FVVJZ9-=Z3K5II^L:7G['O[ M:5JL?[1WP.\,>.-8MH7M]*\<67]I>&_B)HZ%V6&.S\9^&;G3_$)M+="IBL+[ M5+O2 JJG]DJF8J_)'4?^#7G_ ()Z7FJ7.I1?$/\ :UTFRDF,R^'K#XD_"LZ' M;Q-(SQV4']I?!B\U*2TMD*P0OJ%]/>M"BM<7$\Y>1OZ2J* /RN_9<_X(V?\ M!/O]DG5]+\5_#OX&Z;XN^(&F21O9_$3XNW\GCSQ'8S1A M_HVGWUC#X+T34P MZ&=;OPUX7T2YCF=C;W<:+$(_U.B!6*-3NR(T!WEF?(4#YF9Y&9O[Q:21B\5:'XX_: ^ W@GXK>*?"NFKX>\.ZWXDL]3FU/ M3- 74GU1M,MV@N(5:W75-0U+4D6( LQ0(^T,T7UY10 V,L40L06**6*AE4L0 M"2%8EE!/0,2P'!.CS&(,?+D:"RT>[@@9D"LT$4TB0L3&C MNJAC^RY?Y2SE57!Z#GT]OH.O7\#5,IYPP(R=NZX5>.W&8T8GAF/5=?!JS6#PCHJK?S1HE]KUY%#YOHX M(1!%*RF0V\,%K;(79(K>)55%]K-RRY^: <]6N 1W]& ]>...W6K$3!D+K(I) M&Y@O3YN3@\Y SP><\'!%>KX??1W\(O#+$U,9PMP5C:>.A3IQIXW-'EFV*G3P]13=YU*5*,Y0M!MP5C@XM\6?$#C=*'$F;3Q6!6LL/2R^GE= M)/EY95*D:%->W;24>2=1QBE=08^,*(]V 0R#.&+ $C/#D L.P8X+=2!5I,!% M Z;5Q],"H%965@W^2._;U]NAQ5A<;5QTVC'TQ7[E"I[1WG>%91]^@Y)NG%R] MUM+J]N:^J270_-Z:2NJ5O8/WH-?SMOF^5OQN>-_';XM>#O@7\'_B=\8O'][+ MI_@WX7^"O$OC?Q+/&4-]_9GARTEU62WTN)I4\[7K];*6V\,1!U,NIS6,0 >5 M%/\ %#_P0]^%7BC_ (*$?\%.OB[^W;\9K."^LOA)KVK_ !LU*WFO/MFDQ_%G MXD7]];_##0K6V!!@TCX=:?8>(=<\+J#B'_A"/!X;"H2/M/\ X.=OVX;_ ,+^ M'_ ?["O@75$@?XCVVG?$GX]/;,MW+'X,TS6'D^'GA2XMT8E!K_B31I==UN*5 M0Z:?I'A61"8YES^CG_!OS^R'=_LO_L&>&?&'BZTEM?B1^TQ?6WQC\3VUU&$N M-,\+ZIIT%I\-M$D3HDL_AB2V\3RQY&VX\4SQ,H,2DZFA^Z,8"QHJ@@*B@!AA M@ H ##L0.H]:?2 8 & !CT]OPI: "N#\8^"/#7C?1K[0?$NA:=K&EWTK^= M9ZA:)>Q.[AQ]HA$@;[)5!C)<9'+'@=3DG@GM_CTSVX M,RP>$S'"5LNS#!+,L!CJ53#8S 580J8+%T*D+3HXZ$[QEAY)OW9)J4KII]-: M&)K86K3KX?$2P]6G.,X2C)Q;E!\T;.,HR3C+WDXNZ?E=/\N?'G_!.FRO[R74 M/AUXP.@VLBR$>'?$.F1ZK:1RL6*B#5K&ZTZ[B1"0BRW=AK-RR@233W$A9V\I MLO\ @G7\2YKB*"\\<^#%MD"I=2+::O?W4+H )$MC(EI$41@0F8[<$ ?N8ON+ M^S)10.05/]/QI!&&!"L.Y/R@?0T^C_GF95<96X,Q.6X;$ MVJU\GX>S6OD^14J_.Y5,3/"T+QQ$JOP3H\[C'6:A&Y^PY;](3Q7RC"4L'0XB MFZ.$BXX!U:=&M44G%0<>>48N25-)7FI/K)MZGP3\'OV%/ 7P]U2U\0^*=2N? M'>LV,B3Z?::E!]G\/:==@[OMEMI2^8)[H/\ /YTSR,7.63/-??=N@CMX(P% M2&) $4H@"HJ@(C99% 'RJW*C /(J)8\ [20>N1V[]\^GZ<590851DG"@9/4X M'4^YK]QX#\/."?#K+(Y/P1D.4Y-@*=*-*4\%ET*&-Q$83YXK&9AR*KC8QE>< M8SFU&HW444W<_.>(^+.(^,<=/->)\QJYAF-23OV"[_P#::/[7EU\+_$4_QS7XP6?QU/B!?B5XY33?^%DZ M?XDM?%-CJB^%QKJ>&2K>([:"[2RFLX[90#"JQPJ1'^IE%?=GSXR(DQQECEBB M%CA1DE02<(SH,GG"NRC^%F&"7T44 ?F3^UK_ ,$D_P!A;]M#5]0\6_&#X+6% MI\1[H7$;_$SX;7=U\/?'>H?:)KIVD\2ZGH%Q8:)XY,0M^6>H_\ !K'^Q=-J,:A=V!AW:7=/X.N+[3SY0B,3 MH#7[/VL:16UO%'&L4<<$4<<21B)(D2-52-(A% (U10%6,0PA HBCQL$]% ! M1110 4444 %%%?$NF?M83:K^WIXX_8GC^'WD_P#")_LUZ!^T@/B/_P ).+KX??\(6/!;^%K6VMI(I;)]2&J/X\E#JL:2:- @>10#[:HID?,:'> MLF47YU^Z_P H^=?F?Y6ZCYVX(^9NI?0 4444 %%%% !1110 4444 %%%% '@ M?C;]F?\ 9R^(_B6Y\6_$+X ?!;QWXJO1:1W_ (I\:_"SX?>*-;NX],.W1X;W M5]>T*ZUAQIQ55TLQS.+<1QLCMA37N.GVEGI]A96&G6EMI^GV5I;6EC86=LEE M:65G;0I#:VEK9QQQ1VEM;0(D,%LD4201(L2QHJ!1;HH **** "BBB@ HHHH M**** "BBOEZ3]JCX&W'[3>H?L@P>-KE_V@M-^&4GQBNO!B^&M>2&/P#%J$6E MG43XKN-#?P<["?688_[/74&U)0Q$^Y@VT ^H:*:B[4502=JJN2%4G R5554 M$]PJJHZ!0. Z@ HHHH **** "BBB@#P3XZ>#_C/XR\*1:9\"/B[X;^!OCV/6 M?MDWC+Q5\+$^,MC>>'+:SU2"317\(OX\\"[;DZKJ>G:YINK#7+E=+7318MI# M)K/_ (@?\$_? M!.BZQ\5OB5;ZAK7A?X'>"D^->N7FK>.;CP/I":%XN#!(E@U_=S>)!K7A#]RU" MA5" !0 %"XVA<6-GXP^+ M/Q N9H='&JZGI\#7$>"_O=!LA+/%'Q7_!:CPAX=O8 MOV'OBO\ $]_%5C\ OA-^UCI%E\<_$W@WQ9KG@O6/AUX3^*GAK6_ASI7Q"G\2 M>&=8\/\ B30K#P]XGU/0+F75=.NI'MOM@D 96A:7Z"M?^"6W[*_BO0+6YM?B M)^UEXB\+^)=)62%T_;D_:?\ $6C>)]!UFV$X6X35OBA=6FKZ+>6LR207'FS? M;;21)_,*R!V /T@\ ^,]!^(_@3P5\0_"MZ=2\,>//"7ASQGX+-(C>VF.V87]WI]E'Y4V<1OOP M'8*WL'PP^'?A3X0_#7X>?";P'8RZ9X&^%_@;PE\._!FFW%_?:K/I_A3P3H&G M^&O#MC-JFIW%YJ6I2VFCZ99P27^H7=U?7CQM<7=Q/<222M\U_P#!1E4;_@GS M^W<'3S(Y/V-?VGHW3^\H^"/CO M/--\+?"OXR_#C2M:^%'[-&G_ ^T*V_X1K1Y(=,N=&^,VO\ Q(BSXPU?7OB7 MH=A>Z]9^#X2_AWP_X.\5:196J37-N2GZAJ-JJ.> !RS.>!CEF^9CZLWS'J>3 M7S/^Q7''#^QO^R7#$NR*+]F;X#QQI_\&?$SQ+J5O%X;TLW]W\4O$'Q(\4:H^MP2^*AXBTS2= M!\"Z/\/+S^Q1!JJ^,;FXD?2X[/\ P3S_ &D/B/\ M%_"7XDV7QKTCP[HGQP_ M9V^/7Q-_9?\ C-)X(6Z7P5K'Q ^&CZ3,WB_P:E[;6UW;V'BO0_%F@ZU%!CV]LJI;=E_P0X_X54/AI^W?:? JZTN\^#MA_P4M_:$LOAU M=Z1JMQKND7?@BW^'WP6AT>XTG7+VXNKS6-,N+1+>6RU6ZN;BYU"U:"\N)YI9 M6E8 _<8=.>#W'7%?@G\&OVA_^"AW[7OQN_:Z^!?PZ\;_ ]^ WP]_9O_ &K? MC#X&\4?M)3_#;2?B%XLO_"5IXH6T^%OP=^&?@C6[S2/ \?C#1/!NG3:S\2?B M)X\7Q2;>#Q%X4MM)T&:65ED_>ROP]_X)=?&3X>2_'_\ X*L? :/Q!9CXL^'/ M^"AGQ\^,+>'#-&NJ7?@;Q5H7P[\'VVOZ'IA9I]?;1M?\+76AZTL4+1Z3=:GX M>MYI8GU^W60 U=?^,O[9?[ 7QB^"MG^U+\;-%_:Q_93_ &@_B7H/P:3XUWWP MM\&_!KXK? +XH^,WE@^'UIXUT#P%;Z5X!\4_#CQ9J,-5TK2M3\/:PR6 M+:5:;(-/\5_M5&-L<:@. J* )':1QA0,/([.SN/XG9V9CEBS$DG\;O\ @KEX MET?QKX0_9I_9#\.7%AJ_QI_:2_:K^!#>#O#=NBZI=:+X"^&_Q$TOQ]\0/BYJ M&CQM(T?A#X=Z3H<(U75"(R=1O;?9$0&8?LFN=JY!!VC()W$''(+J^+K;P;J'C5;JX\"_"KX;> M!+"+5_B+\6/&5GIFI:=JE_9Z#I,XL_#'A]]6TNS\2^.1%9B155H7^=?B_IW_ M 48_8[\.Z=^T7KW[9>@_M5?#+P3KWARX_:(^$_B_P#9O^''PJ6Q^#^H:[:6 M7Q(\?_!_Q+\+;_3/$^F>)/ 6CW\VK:+X=\;7_CG[+H6D>5J&M:YJEI=3>,_& M/^"CGPP^';?\%,?V+?'_ .T1XR^(7@?X"_%;X,?%']G31_'G@CXN^./@U!X. M^-=OXF'Q \+Z=K?CWP+KGAJ]T$>.].O'TC2K=[Y3JESX:%Y)*H\,-*?L?4?^ M"3?[,&K65[HVL^+/VL-9T?4+=K#5-&UG]LO]I&_TS5+&2+4DGMM4T>[^)T^F M:UIVI6-Y/HTUKJ\4V^R@5)6D<2S _46-BR(Q# LBL0Q0L"0#AC&S1EAT)C9 MD)SM8K@U\$?\%&OV@/B'^S-^SG#\3_AI)G^-?[/W@>>;5](;5].?PU\ M0?C3X0\)^*H4TWS&5;P>&-8U(1Z@R!4E591\PC$7WI;@B" -G<(8PV<@YV+G M(:6=LYSG,\Q]99#\Y_)C_@MA]LT_]@'X@^,+>SFOK;X;?%+]GGXH:_'9J6N+ M;PWX ^.OP_\ $.OZBLK$_P!GP:?HMH]Q?WZ9$-NDSE4!)< _1OXQ:]J?A#X4 M?$WQAI#VZ:[X3^'WCCQ3I,\\;2V<6K:'X2UB\L'N+)G8W4*RP)YL?2:,'LH2 MO'?V&_BUXK^/7['7[,_QK^(;VC^-OBA\&/ 'CSQ5-8VHL;*36]=T.SU*^DM; M)?\ CSM7O+J62WM@/W$3+%_#QS_[7OQX^%WP\_8Q^,/QHUKQ3I-QX U3X(^* M[GPUJ^FZFDP\;S>+_!NHIX%T+P93'*%\+:2!(D/_+%'QN6+_EFI"=J M/I?XS^'/B]XJ\":AH/P3^*WAWX/_ !#NKRQ72O'GB3X:_P#"V-+TZ&&>.[U3 M3;OP4/%?@5+B;4M-2YM[+53XHT\Z;--:W366K&,077XG?\$6?A[^U]??LC_L M^>/(?VL_ S? O_A8/QSN=6^#MU^S3#_PDU_::7^T5\<[+Q;!%\8!\4DETV?Q M1XA67Q U^_@9FT,R-H:6<841+_0FX(W,%WLXV@'@#:KD GG ))!/JWX5^2?_ M 1%NK6?_@F_\%=/%U;33:-\0/VF]+U6&/\ UEKJJ_M5_&'5[2R?J0UO:7D? MF X!=N.AH _6R#F&$DNV8H_FD3RY#\@Y>/RH-CGJR>3#M;(\J/&P?GW;_&_Q MDW_!4SQ#^S:T/AS_ (5U:?L%>$OCX)&\/$>*_P#A,[WX_>._AO*_.+]IWXL_M2>(/C;X1_93_9$ MC\!>$/&FJ>!-3^+GQA^/WQ.T'4_&OASX*?#G4?$]_P"#? 3Z-\/;6Y\-VWC3 MXA^-_$7AOQ6_A6SUW7](T.QT+P%XAN6EUQ5&/T?K\YV^)?@KX:_\%+_&WP]\ M<:^NC:S^TK^RM\"KOX10ZY=F#3_$^M_ CXD?M+1?$?P=HMP\D4=S>Z?X?^*W M@[Q9;^%4$S7:7?B75AM*S%0"Q\+O@+^W3X$^*GA7Q#XZ_;__ .%\?"V*74Q\ M0?AEXW_9>^$7@R[O[*?0]7CMY_ GCGX5?\(??:4;779-)E&EZ]:>*YK>V@DA MO=4U)@+B]_1 # QZ<:KK-'&(8I7V2LB_)(P:3.!D.RY5F!X9@< M,&OBA\7OB5K7Q&UV>/2M!^'FB_$>-_A_IGP_T+3;86?BOQ>/#?CC4K/7M6 M31F?0KFX61/N[]G'P9\>/ ?@F]\/?M#?&[1?V@/&-IXBU"31/B)I/PPT3X27 M^I^#'T^V71['Q)X5\,:]J_A^YURTO?[7-WJ6BV>EZ3>S%Y=.T/3[7R(8O&/V ML/V%?@+^UGK&@^,O%=UXT^&?QO\ AVMYIOP]_:'^!_BR_P# /QK^'G]H&.ZM M;2U\3:/'BVL\R:P_A[Q-;:WI>E)>_P!MI::*E]-.GCW_ 3-^,7QJ\9P M_M3? SXW?$.U^-VL_LC?M#7_ ,$-#^/$&E6>FZC\2]#AT#0?%=E'XS6Q:X\/ M+X\\%V_B.TT+QX /U4CX1!G/R+SG=G@N MT= 41?ZN/AA\B<,TC,/E'#-*!*S#NT@$A/+@-D44 5YHTG62*1(WBD2:!HWC M%Q;SQRC;/%<1;=I#89&1CALL&W@NE?#GP^_X)]?LQ_#'XW:C\=_AUH/CSP-X MMO\ Q=XG\:WWAKPY\9OBUHOPGF\;^*[2;2O$OBJY^$5KXKT_P-=Z]XCT[4Y9 M;RYGT"[MOM-RX@VJ())ONZB@!J'B@#P_XP?!#X9_M >"K?X?_&#PN?%W M@N/Q/X)\;)HTNL:UI6[Q7X%\2Z5XL\)ZBVH>'M=AU2;^R_$VE:=<_8YKJ33V M^SHDOGP0@2^VQ@"- "6 10&+%R0%&"69G9B>NYG$O%NA:3XE\->)+&]TG7]!U^P35](U;2KYG6>TU2QG8Q:A!+%E;6)E'V M$,I3#1*3^;MA_P $??V%-(270]#\"?%;P_X!N+U[Z^^#WAS]HSX_:/\ !VXN MY(X[:2WG^'VD_$:ST06Q$MO>1:2UFOAZV6..&SM;;38UCC_5*B@"* L882YR MYBC+$="Q0%B,2SCKG_EO-_UUD^^WG?Q*^'_A+XM>!?'WPJ\?Z.=>\!?$SPCX MH^'_ (XT(7EQIIUGPIXRT6[T'7=/?5-/OM(UFS36=(O;O1_.TVZ$R(H$-Q"8 MC*/2:* .8\$^#O#GP[\&>$?A_P"#]-.C>$? WAC0/!WA;2&O+_46TKPYX9TJ MTT71--;4-4N[_4[\V.F65K:F\U&^O;^Z,7GW=WFR+<:=>_%3X> M^#?%&C>$/&E_;WOF7,UY>:'J%SJ5VTT_B*2\,\H;Z*^"O[-GP/\ V?)O'B?! MCP%I_@.T^(_BJW\9>+M*TN[U.[TF\US3-#T'PMI[Z1H]QK-[I7AJPTW0O#V@ M6>G:+HFGZ;I.F6%O;VNGV%I!&L$'T-10 U P1 S%F"J&8E268 98E4C4DG)R MJ(I[(HX'X0_LV_\ !/OX:_&SQ-^W3JW[3'P2\6Z)XBM?^"F/[1?Q(^!_C_[5 M\2/@W\03X*\5>"_@[;67B?X=?%#P=J/A;QG=_#WQ5>Z+K,-P=-UF3P]?WVDS M/:P2VT5G-7[P44 ?&/[/G[!W[-7[-/BOQ#\1/AKX&U6Y^*?BNU73O$7Q>^)/ MCKQQ\7?BYJFDVC!;739O'OQ4\2^-M?CTQT4J;&SO],M1&Y#6:-A(?LN,DQH2 MNTE%)7"C:=HRN$>11CIA7=1V=A@E]% 'CWQ>^#?PO^/_ ((USX7?&GP%X8^) M'PX\0E_[8\)^*=,74+"]EMV9;6Y"[+F5;^SD3[18:CI=]INIZ6=AB,,L>$^) M?#G_ 2<_8N\+ZIX8O(O#?Q;U/1/!6LZ/XA\(> _%7[3?[2OBOX?>$=5\/ZN MVOZ/?:5X.\3?%76?#82PFL+=;2UO-.6WBM;>.*2&(NL2_IW10 U=VU=WWMHW M=/O8YZ<=?3BL+Q'X>T7Q7H>M>&?$NDV>N>'M>TV[T?6-%U*!;O3]5TS48G@O M;2Z@96#1SQ2/&RG[H(92"%9=^B@#\S?AO_P2A_82^%OBG3?%'A/X'W%Q-X.O M=2NOA[X:\2?$+XE>,O 'PQU#6M0U.YO+SX:_#OQ3XVE\(^!+G[3J%]K)ET7P M]IS:7_:,<7A2_M;:WMXT^UO@_P#"/P)\"?AGX+^#_P +]&N/#?P\\ >'H/"_ M@S0)-6U[Q"=+T.TB2/3]-35?%U]K&L21V-M"L,8U?4]0NY.?M=W"_&NO>./$'C[7]!\.?&'XMZ7\,-<\?>)-/>QU_Q;J/PIM/ M%5AX'U+Q'K%ABZO+Z7P]>P27,L[H) OF'[OHH CAR8HMS.Y\M,O(GENYVC+/ M'LCV.QY9/+3:25V+C:/%A\"/A/%\<]0_:4C\)J_QNN_AC8_!"\\9C7=;>1OA M=8^,;OXAVGA(>&YM7D\'1K#XJU"[\0?VFOA^VU]A>LDNKO#\A]MHH BMS(8( M3*I64Q1F16"AED**74A9KE00V00MQ<*".)I1^\;YL_:._9-_9]_:T\,V/@G] MH7X6:'\2=%TO4I-6T&\OKB^T3Q1X5U-'$L&J>%O&?A;4= \7^$[Q2HB2?PYJ MD$]Y%%"-3DD(>OIBB@#\^?A#_P $X?V6O@G\1O"/Q=T/1?BCXI^(/@%;UO N MO?$SXX_&_P")]QX(MM1\-ZCX0O[3PMX<\9>-_$NCZ?!/MVJ:EJ^KWE]JVL:G?2?Z1?ZMJUY>ZCJ-P3=7 B=W-/*[/[310 BD%5(.X$ @@[@01P=W?(YSWZT4M% '__V0$! end GRAPHIC 9 tm2131839d1_ex99-1img001.jpg GRAPHIC begin 644 tm2131839d1_ex99-1img001.jpg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tm2131839d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2021-11-04 2021-11-04 0001761612 us-gaap:CommonStockMember 2021-11-04 2021-11-04 0001761612 bcyc:AmericanDepositarySharesMember 2021-11-04 2021-11-04 iso4217:USD shares iso4217:USD shares 0001761612 false 00-0000000 true 8-K 2021-11-04 Bicycle Therapeutics plc X0 001-38916 B900 Babraham Research Campus Cambridge CB22 3AT GB +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ true true XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 04, 2021
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 04, 2021
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One B900
Entity Address, Address Line Two Babraham Research Campus
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB22 3AT
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2131839d1_8k.htm bcyc-20211104.xsd bcyc-20211104_def.xml bcyc-20211104_lab.xml bcyc-20211104_pre.xml tm2131839d1_ex99-1.htm tm2131839d1_ex99-2.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2131839d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bcyc-20211104_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2131839d1_8k.htm" ] }, "labelLink": { "local": [ "bcyc-20211104_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20211104_pre.xml" ] }, "schema": { "local": [ "bcyc-20211104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20211104", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131839d1_8k.htm", "contextRef": "From2021-11-04to2021-11-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://bicycletherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131839d1_8k.htm", "contextRef": "From2021-11-04to2021-11-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bcyc_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://bicycletherapeutics.com/20211104", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 18 0001104659-21-134000-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-134000-xbrl.zip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�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